China CRAMS Market Outlook to 2018 - Manufacturing of APIs and Bulk Drugs to Propel Growth
The industry research publication titled ‘China CRAMS Market Outlook to 2018 – Manufacturing of APIs and Bulk Drugs to Propel Growth’ presents a comprehensive analysis of market size by value of CRAMS services in China. The report entails the market share analysis and company profiles of major players in the CRAMS industry. The future analysis and segmentation by drugs and devices and therapeutic areas have also been discussed in each of the sub-segment.
The CRAMS industry in China has grown at a CAGR of 15.0% during 2007-2013, registering a market size of USD ~ billion in 2013. The CRAMS industry in China specializes in providing basic intermediaries, APIs and bulk drugs. The industry has emerged as a low-price leader compared to developed industries such as US and Europe. The industry is presently in the growth phase, with a large number of contract research and manufacturing organizations operating in the country. The CMO industry of China accounted for USD 2.6 billion growing at a CAGR of 15.2% during 2007-2013 while the revenues of CRO industry reached USD 1.2 billion in 2013. The increasing capabilities of the Chinese organizations in the research department have been the major reason driving the growth of Chinese CRO industry. Rising incidence of chronic diseases has largely promoted use of contract research and manufacturing services. Nearly 80% of the deaths in China are due to non-communicable diseases and injuries. Some of the most well researched areas in the CRAMS drug market include oncology, cardiovascular diseases, infectious diseases and respiratory diseases. Oncology reaped the largest revenues for the CRAMS industry of drugs of China with revenues of USD ~ million in 2013, growing at a rate of 13.9% during 2007-2013. Researches for the medication of infectious diseases held the second position with a market size of USD ~ million in 2013, increasing from USD ~ million in 2007. Some of the other emerging research areas of the industry include metabolic disorders, cardiovascular diseases and central nervous system disorders. The Chinese CRAMS industry is highly fragmented with over 500 CROs and more than 100 drug manufacturing sites for APIs and finished products in the country. Some of the leading local players of the industry include Wuxi AppTec, 2Y Chem and Tigermed while the leading global players in the country are Quintiles, Covance and others.
The large and growing population of China is expected to boost up the demand for modern medicines which would increase the investments made by the pharmaceutical companies in the country. The focus of the contract research organizations is expected to shift from chemistry to new areas such as biology, DMPK, formulation and clinical research. Factors such as rise in the exchange rate, labor cost would majorly be responsible for driving the market. The revenue of the market is most likely to advance at a rate of 19.5% during 2013-2018 to reach a size of USD ~ billion by 2018.
KEY TOPICS COVERED IN THE REPORT
The CRAMS industry in China has grown at a CAGR of 15.0% during 2007-2013, registering a market size of USD ~ billion in 2013. The CRAMS industry in China specializes in providing basic intermediaries, APIs and bulk drugs. The industry has emerged as a low-price leader compared to developed industries such as US and Europe. The industry is presently in the growth phase, with a large number of contract research and manufacturing organizations operating in the country. The CMO industry of China accounted for USD 2.6 billion growing at a CAGR of 15.2% during 2007-2013 while the revenues of CRO industry reached USD 1.2 billion in 2013. The increasing capabilities of the Chinese organizations in the research department have been the major reason driving the growth of Chinese CRO industry. Rising incidence of chronic diseases has largely promoted use of contract research and manufacturing services. Nearly 80% of the deaths in China are due to non-communicable diseases and injuries. Some of the most well researched areas in the CRAMS drug market include oncology, cardiovascular diseases, infectious diseases and respiratory diseases. Oncology reaped the largest revenues for the CRAMS industry of drugs of China with revenues of USD ~ million in 2013, growing at a rate of 13.9% during 2007-2013. Researches for the medication of infectious diseases held the second position with a market size of USD ~ million in 2013, increasing from USD ~ million in 2007. Some of the other emerging research areas of the industry include metabolic disorders, cardiovascular diseases and central nervous system disorders. The Chinese CRAMS industry is highly fragmented with over 500 CROs and more than 100 drug manufacturing sites for APIs and finished products in the country. Some of the leading local players of the industry include Wuxi AppTec, 2Y Chem and Tigermed while the leading global players in the country are Quintiles, Covance and others.
The large and growing population of China is expected to boost up the demand for modern medicines which would increase the investments made by the pharmaceutical companies in the country. The focus of the contract research organizations is expected to shift from chemistry to new areas such as biology, DMPK, formulation and clinical research. Factors such as rise in the exchange rate, labor cost would majorly be responsible for driving the market. The revenue of the market is most likely to advance at a rate of 19.5% during 2013-2018 to reach a size of USD ~ billion by 2018.
KEY TOPICS COVERED IN THE REPORT
- The market size of the China CRAMS market in terms of value in the last years (2007 - 2013)
- China CRAMS market segmentation by CMO and CRO service
- China CRAMS market segmentation by Drugs and Devices
- China CRAMS for Drugs Market Segmentation by Therapeutic Areas
- Trends and Developments in the CRAMS market in China
- Government Rules and Regulations in the CRAMS market in China
- Competitive landscape players operating in CRAMS market of China (such as Tigermed, Wuxi AppTec, Shanghai Pharma Corporation and Others)
- Future projections and macro economic factors of CRAMS market in China.
1. CHINA CRAMS MARKET INTRODUCTION AND SIZE, 2007-2013
2. CHINA CRAMS MARKET SEGMENTATION
2.1. By CMO and CRO, 2007-2018
2.2. By Drugs and Devices Market, 2007-2018
2.2.1. China CRAMS for Drugs Market Segmentation by Therapeutic Classes, 2007-2018
3. COMPETITIVE LANDSCAPE OF MAJOR PLAYERS IN CHINA CRAMS MARKET
4. GOVERNMENT REGULATIONS IN CHINA CRAMS MARKET
5. TRENDS AND DEVELOPMENTS IN CHINA CRAMS INDUSTRY
Focus on API and Bulk Drug Manufacturing
Rising Clinical Trial Activities
6. CHINA CRAMS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2014-2018
7. MACROECONOMIC FACTORS AFFECTING CHINA CRAMS MARKET
7.1. Ageing Population (55 Years and Above), 2007-2018
7.2. Total Healthcare Expenditure, 2007-2018
7.3. Gross Domestic Product of China, 2007-2018
7.4. Expenditure on Drug Development, 2007-2018
7.5. Personal Disposable Income per Household, 2007-2018
8. APPENDIX
8.2. Market Definitions
8.2. Abbreviations
8.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
8.4. Disclaimer
2. CHINA CRAMS MARKET SEGMENTATION
2.1. By CMO and CRO, 2007-2018
2.2. By Drugs and Devices Market, 2007-2018
2.2.1. China CRAMS for Drugs Market Segmentation by Therapeutic Classes, 2007-2018
3. COMPETITIVE LANDSCAPE OF MAJOR PLAYERS IN CHINA CRAMS MARKET
4. GOVERNMENT REGULATIONS IN CHINA CRAMS MARKET
5. TRENDS AND DEVELOPMENTS IN CHINA CRAMS INDUSTRY
Focus on API and Bulk Drug Manufacturing
Rising Clinical Trial Activities
6. CHINA CRAMS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2014-2018
7. MACROECONOMIC FACTORS AFFECTING CHINA CRAMS MARKET
7.1. Ageing Population (55 Years and Above), 2007-2018
7.2. Total Healthcare Expenditure, 2007-2018
7.3. Gross Domestic Product of China, 2007-2018
7.4. Expenditure on Drug Development, 2007-2018
7.5. Personal Disposable Income per Household, 2007-2018
8. APPENDIX
8.2. Market Definitions
8.2. Abbreviations
8.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
8.4. Disclaimer
LIST OF FIGURES
Figure 1: China CRAMS Market Size on the Basis of Revenue in USD Billion, 2007-2013
Figure 2: China CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 3: China CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in Percentage, 2007-2013
Figure 4: China CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Figure 5: Aged Population in China in Million, 2007-2018
Figure 6: China Healthcare Expenditure in USD Billion, 2007-2018
Figure 7: Gross Domestic Product of China in USD Billion, 2007-2018
Figure 8: Pharmaceutical Industry Spending on Drug Development in USD Billion, 2007-2018
Figure 9: China per Capita Disposable Income in USD Thousands, 2007-2018
Figure 1: China CRAMS Market Size on the Basis of Revenue in USD Billion, 2007-2013
Figure 2: China CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 3: China CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in Percentage, 2007-2013
Figure 4: China CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Figure 5: Aged Population in China in Million, 2007-2018
Figure 6: China Healthcare Expenditure in USD Billion, 2007-2018
Figure 7: Gross Domestic Product of China in USD Billion, 2007-2018
Figure 8: Pharmaceutical Industry Spending on Drug Development in USD Billion, 2007-2018
Figure 9: China per Capita Disposable Income in USD Thousands, 2007-2018
LIST OF TABLES
Table 1: Investments by Major Pharmaceutical MNCs in China
Table 2: China CMO and CRO Market Size on the Basis of Revenue in USD Billion, 2007-2013
Table 3: China CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 4: China CMO and CRO Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 5: Acquisitions in China CRAMS Market, 2007-2010
Table 6: China CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in USD Million, 2007-2013
Table 7: China CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 8: China CRAMS Market Segmentation Drugs and Devices Market Future Projections on the Basis of Revenue in USD Million, 2014-2018
Table 9: China CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in Percentage, 2007-2013
Table 10: China CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue in USD Million, 2007-2013
Table 11: China CRAMS for Drugs Market Segmentation on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 12: China CRAMS for Drugs Market Future Projection on the Basis of Revenue in USD Million, 2014-2018
Table 13: Number of Clinical Studies Performed in Different Therapeutic Areas in China, 2007-2013
Table 14: Competitive Landscape of Major Players in China CRAMS Market
Table 15: Revenue of Major Players in China CRAMS Market in USD Million, 2010-2013
Table 16: Clinical Trials Carried by Leading Players in China, 2010
Table 17: Correlation Matrix for China CRAMS Market
Table 18: Regression Coefficients Output
Table 1: Investments by Major Pharmaceutical MNCs in China
Table 2: China CMO and CRO Market Size on the Basis of Revenue in USD Billion, 2007-2013
Table 3: China CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 4: China CMO and CRO Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 5: Acquisitions in China CRAMS Market, 2007-2010
Table 6: China CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in USD Million, 2007-2013
Table 7: China CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 8: China CRAMS Market Segmentation Drugs and Devices Market Future Projections on the Basis of Revenue in USD Million, 2014-2018
Table 9: China CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in Percentage, 2007-2013
Table 10: China CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue in USD Million, 2007-2013
Table 11: China CRAMS for Drugs Market Segmentation on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 12: China CRAMS for Drugs Market Future Projection on the Basis of Revenue in USD Million, 2014-2018
Table 13: Number of Clinical Studies Performed in Different Therapeutic Areas in China, 2007-2013
Table 14: Competitive Landscape of Major Players in China CRAMS Market
Table 15: Revenue of Major Players in China CRAMS Market in USD Million, 2010-2013
Table 16: Clinical Trials Carried by Leading Players in China, 2010
Table 17: Correlation Matrix for China CRAMS Market
Table 18: Regression Coefficients Output
